Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 423

1.

Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.

Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O.

Curr Med Res Opin. 2005 Oct;21(10):1583-94.

PMID:
16238898
2.

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE.

JAMA. 2003 Nov 26;290(20):2685-92.

PMID:
14645310
3.

Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population.

Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, Graham J.

Clin Ther. 2013 Aug;35(8):1201-10. doi: 10.1016/j.clinthera.2013.06.005. Epub 2013 Jul 16.

PMID:
23867114
4.

Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE.

Ann Intern Med. 1999 Dec 21;131(12):927-34.

PMID:
10610643
5.

Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.

Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY.

Am J Med. 2014 Oct;127(10):972-8. doi: 10.1016/j.amjmed.2014.05.035. Epub 2014 Jun 12.

PMID:
24929021
6.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

7.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Jul;30(7):1317-25. doi: 10.1185/03007995.2014.907140. Epub 2014 Apr 2.

PMID:
24650301
8.

Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation.

Siu CW, Tse HF.

Circ Arrhythm Electrophysiol. 2014 Apr;7(2):300-6. doi: 10.1161/CIRCEP.113.000858. Epub 2014 Mar 7.

9.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

10.
11.

[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin].

Hu DY, Zhang HP, Sun YH, Jiang LQ; Antithrombotic Therapy in Atrial Fibrillation Study Group.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Apr;34(4):295-8. Chinese.

PMID:
16776915
12.

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE.

N Engl J Med. 2003 Sep 11;349(11):1019-26.

13.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

14.

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.

Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.

Am J Geriatr Pharmacother. 2009 Jun;7(3):159-66. doi: 10.1016/j.amjopharm.2009.06.002.

PMID:
19616184
15.

[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].

Selçuk H, Selçuk MT, Maden O.

Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8. Review. Turkish.

16.

Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.

Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH.

J Gen Intern Med. 2005 Dec;20(12):1114-9.

17.
18.

International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.

Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR.

Curr Med Res Opin. 2014 Dec;30(12):2437-42. doi: 10.1185/03007995.2014.957822. Epub 2014 Sep 2.

PMID:
25170587
19.

The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS.

Ann Intern Med. 2009 Sep 1;151(5):297-305.

20.

Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.

Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF.

J Electrocardiol. 2013 Jan-Feb;46(1):45-50. doi: 10.1016/j.jelectrocard.2012.08.011. Epub 2012 Oct 11.

PMID:
23063241

Supplemental Content

Support Center